A breakthrough analysis of investment on global health R&D, delivered for real impact.
Policy Cures Research (PCR) is a global health research and policy organisation, with a mission to improve the health of the world’s most disadvantaged people. The sad reality is that millions of people in the world suffer ill health because there is no commercial incentive to develop the products they need. PCR has been working to provide the evidence and research to change that, by using evidence to drive medical research and biomedical innovation for historically neglected and underfunded health issues.
The good news, uncovered by PCR’s own research, was that despite being dwarfed by global health investment in other areas such as cancer and biopharma, R&D for neglected diseases yielded a staggering health and economic return to society of $405 for every $1 invested.
This return stems chiefly from modelling the lives saved and, in turn, years of life saved (measured using Disability-Adjusted Life Years or ‘DALYs’ averted) by breakthrough drugs, diagnostics, vaccines and vector control products created to tackle poverty-related neglected diseases.
Better yet, PCR’s work showed that this unprecedented return has exponential and extrapolating value over the next few years – even against a relatively minor investment of $4b billion compared to a global overall R&D spend of $2.475 trillion. Put simple, investment in neglected disease R&D was an incredibly compelling investment for global health organisations and governments.
But these numbers were just that – numbers on a spreadsheet. They needed to be contextualised and made accessible to a wide array of policy influences, global health professionals, funders and the public. If this story was going to have impact, it needed a narrative. Anthologie worked closely with PCR to develop the Evidence for Impact Report – a global ‘scrollytelling’ digital experience and 360° immersive live film presentation to bring this important research to an international audience.